Blinding eye disease linked with heart disease and stroke
Mount Sinai study is among the first to link cardiovascular risk to a specific form of age-related macular degeneration.
Research to Prevent Blindness awards grant to OU Department of Ophthalmology
The University of Oklahoma Health Sciences Center has received an unrestricted grant from Research to Prevent Blindness for $575,000 over 5 years to support eye research conducted by the Department of Ophthalmology.
Wills Eye Hospital names new co-chief residents
Charles Brodowski, MD, and Patrick Rapuano, MD, have been named co-chief residents at Wills Eye Hospital, and will lead the team of resident doctors on staff, focusing on training and recruitment while attending to their own medical resident duties.
Study: Patients prefer port delivery of ranibizumab
According to investigators, patients with age-related macular degeneration like the port delivery system for ranibizumab because it requires fewer treatments and there is less discomfort.
Measuring levels of proteins in eye fluid may accurately predict need for lifelong macular degeneration therapy
A team of investigators form Johns Hopkins Medicine say they’ve discovered that levels of a specific protein appears to help accurately predict whether people with the wet form of age-related macular degeneration may need lifelong, frequent eye injections to preserve vision or if they can be safely weaned off the treatments.
Efficacy of Notal Vision OCT device demonstrated by a series of scientific and clinical work
Investigators show the effectiveness of Home-OCT based remote monitoring model.
When it comes to ADHD and ASD, the eyes could reveal all
Investigators have found that recordings from the retina could identify distinct signals for both attention deficit hyperactivity disorder and autism spectrum disorder, providing a potential biomarker for each condition.
Self-plugging microneedles offer potential to improve delivery of drugs into the eye
LIGHTSITE III trial data demonstrates improvement in vision in intermediate dry AMD
LumiThera Inc. noted that the trial results demonstrated statistically significant improvement in the prespecified primary endpoint in BCVA at 13 months in the PBM treatment group over the sham-treatment group.
Foundation Fighting Blindness announces leadership changes
Jason Menzo is named CEO, while Russell Kelley, PhD, MBA, will become managing director of the RD Fund. Ben Yerxa, PhD, will take the helm of Opus Genetics, the first RD Fund- and foundation-backed spin-off company.
Nacuity Pharmaceuticals announces $16.5 million Series B financing
Foundation Fighting Blindness is among a group of investors offering financial support for Nacuity’s efforts to stop oxidative tissue damage, a driver of blinding eye diseases.
Major advances in AMD address urgent, unmet need among patients
Study demonstrates results of pegcetacoplan as a geographic atrophy therapy.
NIH study confirms benefit of supplements for slowing age-related macular degeneration
After 10 years, AREDS2 formula shows increased efficacy compared to original formula, benefit of eliminating beta-carotene.
Study: Investigators make key discovery in AMD
According to the study by a team of researchers from the University of California Irvine and University of Southern California, treatment with Humanin G reduced protein levels of inflammation markers that become elevated in age-related macular degeneration.
Health Canada approves faricimab injection for the treatment of wet AMD, DME
Faricimab is the first treatment for wet AMD and DME in Canada that acts by targeting both VEGF-A and Ang-2, two key drivers of vascular instability that have been associated with vision-threatening retinal conditions.
AffaMed Therapeutics announces first patient dosed in the Phase 1 clinical trial of AM712 in retinal disease
The study will investigate the safety, tolerability, pharmacokinetics, and efficacy of AM712 in subjects with neovascular age-related macular degeneration.
Effect of drusen and atrophy in dry AMD on automated segmentation in OCT images
Alterations of the outer retinal layers from age-related macular degeneration (AMD) can interfere with the automated segmentation of the individual retinal layer thicknesses when using macular optical coherence tomography (OCT).
Retinal cell map could advance precise therapies for blinding diseases
A discovery by investigators at the National Eye Institute sheds light on tissue targeted by age-related macular degeneration and other diseases.
VLRC Eye Van making 50th anniversary tour
The Eye Van, operated by Vision Loss Rehabilitation Canada, is a mobile medical clinic that delivers eye care in northern Ontario communities where ophthalmology services aren't readily available.
MacuLogix reaches milestone with 1 million dark adaptation tests
As more and more practices embrace dark adaptation testing, AdaptDx technology has become a staple in primary eye care.
Unraveling genes, mutations in inherited retinal diseases
Variable TULP1 missense mutations in inherited retinal diseases.
Axitinib Intravitreal Implant for wet AMD delivered high drug levels to retinal tissue
The intravitreal implant (OTX-TKI) is being evaluated to treat wet age-related macular degeneration in a phase 1b clinical trial.
Retrospective study of AMD remote monitoring shows improved outcomes for patients
According to the ALOFT study, patients demonstrate improved long-term vision in real-world setting after wet AMD conversion compared to current standard of care.
Outlook Therapeutics submits Biologics License Application to FDA for ONS-5010 as a treatment for Wet AMD
If the BLA is approved, the company could receive 12 years of marketing exclusivity for an FDA-approved alternative for the most frequently used anti-VEGF treatment in wet AMD patients in the United States.
Graybug Vision announces pipeline expansion
The company is planning a Phase 2 trial with an optimized formulation in wet AMD that is expected to start in fourth quarter of 2022.
Apellis announces longer-term data from Phase 3 DERBY and OAKS studies for geographic atrophy
According to the company, pegcetacoplan demonstrated continuous and clinically meaningful effects at month 18 in the studies, which also found that treatment effects in DERBY were comparable to OAKS during months 6 to 18. The combined 18-month data show the potential for improving treatment effects over.
Study: Sound can stimulate blind retina to transmit signals to the brain
Ultrasonic retinal prosthesis has been achieved by a research group at UCLA. It is a step towards a non-invasive retinal prosthesis that works without invasive eye surgery.
The difference between night and day: Circadian clock may offer protection to aging eyes
Investigators studying old flies have gained some new insight into retinal degeneration, seeking an understanding "of the molecular mechanisms that drive age-associated changes and the external and internal factors that influence them.”
Foundation Fighting Blindness, InformedDNA screening patients for ProQR's pivotal Usher syndrome and retinitis pigmentosa clinical trials
Trial recruitment is enabled by the Foundation Fighting Blindness' patient registry, My Retina Tracker Registry, which includes gene
Neurotech platform delivers biological agent over extended period to slow progression of retinal-based diseases
Rich Small, CEO of Neurotech, provides updates on the company’s pipeline that is the culmination of nearly 2 decades of research.
2 Clarke Drive Cranbury, NJ 08512